AJ1-11095, a type II JAK2 inhibitor, shows promising clinical responses in myelofibrosis, outperforming existing type I JAK2 inhibitors in early trials.
- In the news
Myeloproliferative Neoplasms: Diagnosis and Treatment
Moving in Cancer Discovery.
- Moved this week
- 1
Rebuilt
Moved this week
Latest in Myeloproliferative Neoplasms: Diagnosis and Treatment
Newest first · last 60 days
CALR-mutated myeloproliferative neoplasms originate mainly from expansion of Vwf-positive, platelet-biased hematopoietic stem cells, with CALRdel52 mutations showing greater amplification.
Fibrocytes are the main collagen-producing cells in JAK2V617F-mutated myelofibrosis, accounting for nearly two-thirds of collagen production in the bone marrow.
- Open access
Genomic evolution in myeloproliferative neoplasms reveals distinct pathways to disease progression and therapy-related mutagenesis.
- Open access
Polyclonal competition drives clonal hematopoiesis, with about 3 fit clones entering the HSC pool annually and rarely exceeding 5% frequency, mainly emerging later in life.
- Open access
Aberrant splicing of MBD1 produces the MBD1-L isoform, driving myelodysplastic syndromes (MDS) by reshaping the epigenome and causing hematopoietic defects in humans.
- Open access
Menin inhibition reduces megakaryocyte proliferation and fibrosis, showing promise as a therapy for myeloproliferative neoplasms with potent anti-tumor activity.
- Open access
RAAS inhibitors significantly decrease hemoglobin levels in sickle cell disease patients and mouse models, worsening anemia by approximately 0.5 g/dL.
- Open access
Likelihood-based calibration of JAG1 MAVE data enhances variant classification, increasing pathogenic variant detection from 486 to 610 and supporting clinical decision-making.
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4